CD4 cell count and HIV VL stratified by lymphoma subtype at lymphoma diagnosis, NA-ACCORD (N = 717)
| . | TCL and NK/TCL (n = 52) . | BL (n = 101) . | PCNSL (n = 64) . | DLBCL (n = 500) . | P* . |
|---|---|---|---|---|---|
| Patients with any CD4 measurement, no. (%) | 45 (87) | 96 (95) | 51 (80) | 467 (93) | .001†‡ |
| Patients with CD4 measurement within 3 y before cancer diagnosis§, no. (%) | 40 (77) | 92 (91) | 45 (70) | 424 (85) | .002† |
| CD4 (cells/µL), median (IQR) | 142 (83-469) | 309 (170-491) | 45 (10-128) | 182 (72-372) | <.001† |
| Patients with any VL measurement, no. (%) | 44 (85) | 96 (95) | 50 (78) | 467 (93) | <.001†‡ |
| Patients with VL measurement within 3 y before cancer diagnosis§, no. (%) | 38 (73) | 92 (91) | 44 (69) | 427 (85) | <.001† |
| VL (copies/mL), median (IQR) | 400 (48-38 140) | 1738 (50-23 422) | 72 550 (2941-266 305) | 6510 (75-110 362) | <.001† |
| . | TCL and NK/TCL (n = 52) . | BL (n = 101) . | PCNSL (n = 64) . | DLBCL (n = 500) . | P* . |
|---|---|---|---|---|---|
| Patients with any CD4 measurement, no. (%) | 45 (87) | 96 (95) | 51 (80) | 467 (93) | .001†‡ |
| Patients with CD4 measurement within 3 y before cancer diagnosis§, no. (%) | 40 (77) | 92 (91) | 45 (70) | 424 (85) | .002† |
| CD4 (cells/µL), median (IQR) | 142 (83-469) | 309 (170-491) | 45 (10-128) | 182 (72-372) | <.001† |
| Patients with any VL measurement, no. (%) | 44 (85) | 96 (95) | 50 (78) | 467 (93) | <.001†‡ |
| Patients with VL measurement within 3 y before cancer diagnosis§, no. (%) | 38 (73) | 92 (91) | 44 (69) | 427 (85) | <.001† |
| VL (copies/mL), median (IQR) | 400 (48-38 140) | 1738 (50-23 422) | 72 550 (2941-266 305) | 6510 (75-110 362) | <.001† |
The CD4 cell count and VL exhibited here represent values measured either at time of cancer diagnosis or up to 3 years before cancer diagnosis.
P values for the comparison between patients in different lymphoma groups (Burkitt’s, PCNSL, DLBCL, and TCL and NK/TCLs) were calculated using Kruskal-Wallis and χ2 tests for non-normally distributed continuous variables and categorical variables, respectively.
Bonferroni adjusted P values for pairwise comparison: patients with any CD4 measurement: PCNSL vs Burkitt’s, DLBCL: .02, .005, patients with CD4 measurement within 3 years before cancer diagnosis: PCNSL vs Burkitt’s, DLBCL: .007, .04, median CD4 count: TCL and NK/TCL vs PCNSL: .001, Burkitt’s vs PCNSL, DLBCL: <.001, <.001, DLBCL vs PCNSL <.001, patients with any viral load measurement: PCNSL vs Burkitt’s, DLBCL: .01, .002, patients with viral load measurement within 3 years before cancer diagnosis: Burkitt’s vs TCL and NK/TCL, PCNSL: .04, .003, PCNSL vs DLBCL: .008, median viral load: PCNSL vs TCL and NK/TCL, Burkitt’s, DLBCL: .002, <.001, .02.
P values based on Fisher’s exact test because of some small cell counts.
The vast majority of patients had at least 1 HIV RNA level and 1 CD4 level measured within 3 months before the diagnosis of lymphoma.